ABBV Stock Analysis: Buy, Sell, or Hold?
ABBV - ABBVIE INC.
$234.04
4.03 (1.75%)
▲
5d:
+5.62%
30d:
+9.11%
90d:
+14.2%
HOLD
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Smart Money Distribution
None View Scanner →
Strength: 8.0/10
Get Alerted When ABBV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ABBV shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ABBV shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$352.33
Based on 9.0% avg growth
INTRINSIC VALUE TODAY
$218.77
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABBV is currently trading at $234.04, which is considered extended relative to its 30-day fair value range of $213.31 to $225.91. The stock's valuation (Forward PE: 14.2) is in line with its historical norms (14.1). At these levels, the market is pricing in 0.1% annual earnings growth.
Technical Outlook: Technically, ABBV is in a strong uptrend. The price is approaching resistance at $232.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $253.55 (+10.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ABBV is in a strong uptrend. The price is approaching resistance at $232.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $253.55 (+10.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$213.31 -
$225.91
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.9%
Protect Your Profits
Holding ABBV? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($253.55)
- BULLISH: Expecting earnings turnaround to 0.1% growth with 12.4% revenue growth
Trading Range Analysis
30-Day Trading Range
$213.31 -
$225.91
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$215.37
Resistance Level
$232.32
Current Trend
Strong Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.16
Wall Street Target
$253.55
(+10.2%)
Revenue Growth (YoY)
12.4%
Earnings Growth (YoY)
-46.2%
Profit Margin
5.8%
Valuation Premium vs History
+0.1% premium
PE vs Historical
14.2 vs 14.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.1%
(market-implied from PE analysis)
1-Year Target
$230.24
(+0%)
2-Year Target
$230.47
(+0%)
3-Year Target
$230.70
(+0%)
3-Yr Target (if PE normalizes)
(PE: 14→14)
PE COMPRESSION
$229.77
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 14.1%)
$525.29
(+128%)
Base:
(SPY PE: 14.2, Growth: 14.1%)
$341.44
(+48%)
Bear:
(PE: 12.0, Growth: 14.1%)
$290.23
(+26%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Forward PE: 15.20 | Forward EPS (Implied): $15.13
Bull Case
$277.74
(+21%)
Analyst growth 15.0%, PE expands to 16.0
Base Case
$230.01
(0%)
Market implied 0.0%, PE stable at 15.2
Bear Case
$175.96
(-24%)
Severe decline -15.0%, PE contracts to 13.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 23, 2026 12:47 PM ET
Data refreshes hourly during market hours. Next update: 1:47 PM
Data refreshes hourly during market hours. Next update: 1:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABBV showing a specific setup today?
Insider Activity (6 Months)
2
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-03-30
David Ryan Purdue
SELL
5230 shares
2026-03-04
Perry C Siatis
SELL
22381 shares
2026-02-25
Featured in Portfolios
ABBV is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1219 | 53 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 58 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 60 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 59 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$130 | 59 HOLD |
Advanced ABBV Option Strategies
Professional options setups generated by AI based on today's ABBV price and gamma walls.
